Literature DB >> 17395110

Addition of fresh frozen plasma as a source of complement to rituximab in advanced chronic lymphocytic leukaemia.

Abraham Klepfish1, Amichai Schattner, Hussam Ghoti, Eliezer A Rachmilewitz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17395110     DOI： 10.1016/S1470-2045(07)70106-7

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  12 in total

1.  NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement.

Authors:  Siao-Yi Wang; Emilian Racila; Ronald P Taylor; George J Weiner
Journal:  Blood       Date:  2007-11-16       Impact factor: 22.113

Review 2.  Rituximab: mechanism of action.

Authors:  George J Weiner
Journal:  Semin Hematol       Date:  2010-04       Impact factor: 3.851

Review 3.  Evolution of anti-CD20 monoclonal antibody therapeutics in oncology.

Authors:  Ezogelin Oflazoglu; Laurent P Audoly
Journal:  MAbs       Date:  2010-01-30       Impact factor: 5.857

Review 4.  Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies.

Authors:  Ronald P Taylor; Margaret A Lindorfer
Journal:  Curr Opin Immunol       Date:  2008-07-01       Impact factor: 7.486

5.  Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients.

Authors:  Frank J Beurskens; Margaret A Lindorfer; Mohammed Farooqui; Paul V Beum; Patrick Engelberts; Wendy J M Mackus; Paul W H I Parren; Adrian Wiestner; Ronald P Taylor
Journal:  J Immunol       Date:  2012-02-24       Impact factor: 5.422

Review 6.  Anti-CD20 monoclonal antibodies: historical and future perspectives.

Authors:  Sean H Lim; Stephen A Beers; Ruth R French; Peter W M Johnson; Martin J Glennie; Mark S Cragg
Journal:  Haematologica       Date:  2009-09-22       Impact factor: 9.941

7.  An Fc Double-Engineered CD20 Antibody with Enhanced Ability to Trigger Complement-Dependent Cytotoxicity and Antibody-Dependent Cell-Mediated Cytotoxicity.

Authors:  Tim Wirt; Sophia Rosskopf; Thies Rösner; Klara Marie Eichholz; Anne Kahrs; Sebastian Lutz; Anna Kretschmer; Thomas Valerius; Katja Klausz; Anna Otte; Martin Gramatzki; Matthias Peipp; Christian Kellner
Journal:  Transfus Med Hemother       Date:  2017-09-11       Impact factor: 3.747

Review 8.  Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy.

Authors:  Christian Kellner; Anna Otte; Elisa Cappuzzello; Katja Klausz; Matthias Peipp
Journal:  Transfus Med Hemother       Date:  2017-09-08       Impact factor: 3.747

9.  Construction and characterization of an anti-CD20 mAb nanocomb with exceptionally excellent lymphoma-suppressing activity.

Authors:  Hua-Fei Li; Cong Wu; Ting Chen; Ge Zhang; He Zhao; Chang-Hong Ke; Zheng Xu
Journal:  Int J Nanomedicine       Date:  2015-07-30

10.  Synergistic anti-tumor therapy by a comb-like multifunctional antibody nanoarray with exceptionally potent activity.

Authors:  Huafei Li; Yun Sun; Di Chen; He Zhao; Mengxin Zhao; Xiandi Zhu; Changhong Ke; Ge Zhang; Cheng Jiang; Li Zhang; Fulei Zhang; Huafeng Wei; Wei Li
Journal:  Sci Rep       Date:  2015-10-28       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.